Clinical Trial

PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

Name: PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan — clinical trial record (NCT07484269)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PULSE

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer

Trial Details

NCT Number	NCT07484269
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Metastatic Prostate Cancer
Enrollment	753 participants
Start Date	2026-08-01
Primary Completion	2031-07-31 (estimated)
Study Completion	2031-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-20